Slide 1: Company Overview: A Leader in Global Health & Infectious Diseases
Company Overview A Leader in Global Health & Infectious Diseases
Slide 2: Forward Looking Statements
Forward Looking Statements 2
Slide 3: Contents
Contents 1 About SIGA 2 The Smallpox Threat 3 TPOXX®: A Differentiated Product 4 Financial Summary
Slide 4: SIGA At A Glance
SIGA At A Glance TPOXX(1) 30+ Countries Strong Expertise Robust Balance Sheet A Foundational Franchise Where Products Infectious Disease, Health Disciplined & Trusted Treatment Have Been Sold Security, and Government Cash Management for Smallpox Contracting Who We Are Strategic Priorities SIGA is a
Slide 5: SIGA is a Leader in Global Health Security
SIGA is a Leader in Global Health Security Fully Integrated Infectious Disease Capabilities Foundation for Continued Attractive Growth • Commercial-stage pharmaceutical company operating within • Opportunities for TPOXX expansion (post-exposure prophylaxis infectious disease and health security ”PEP
Slide 6: SIGA's Path to Maximize Shareholder Value
SIGA’s Path to Maximize Shareholder Value External Trends Greater awareness of the need for preparedness Increased vulnerability to orthopoxviruses Government Relationships Higher risk of smallpox outbreaks Long-standing collaboration Core Capabilities with key U.S. government agencies Mor
Slide 7: Experienced Leadership in Infectious Diseases and Government Relations
Experienced Leadership in Infectious Diseases and Government Relations Diem Nguyen, PhD, MBA Dan Luckshire Chief Executive Officer Chief Financial Officer Larry Miller Dennis Hruby General Counsel Chief Scientific Officer 7
Slide 8: The Smallpox Threat
The Smallpox Threat
Slide 9: Smallpox: Historic Milestones
Smallpox: Historic Milestones Highly contagious and fatal disease in susceptible population 2017 2018 2021 2022 2024 2024 Canadian researchers U.S. FDA Health Canada EMA and MHRA (UK) U.S. Bipartisan Commission Japan’s PDMA approves synthesize horsepox, a approves approves approve Tecovirimat- on Bi
Slide 10: Smallpox Remains a Significant Threat Today
Smallpox Remains a Significant Threat Today Current geopolitical environment heightens the need for vigilance More than Smallpox can spread The ongoing geopolitical Smallpox globally before issues and advancements continues to 30% The Growing pose a serious global threat. Historic 300M symptoms appe
Slide 11: TPOXX: A Differentiated Product
TPOXX: A Differentiated Product
Slide 12: TPOXX: The Essentials
TPOXX: The Essentials A highly targeted antiviral treatment against orthopoxviruses, including smallpox As the first FDA-approved antiviral treatment for smallpox, TPOXX was among the first therapies delivered to the U.S. SNS under Project BioShield. TPOXX’s was developed in partnership with, and wi
Slide 13: TPOXX is a Clinically Differentiated Medical Countermeasure
TPOXX is a Clinically Differentiated Medical Countermeasure Antivirals Vaccines TPOXX ACAM2000® TEMBEXA® IMVANEX/IMVAMUNE/ Tecovirimat SIGA, TEPOXX (plus other replicating (CMX001/brincidofovir) JYNNEOS® (MVA-BN®) (ST-246/tecovirimat) vaccinia vaccine) First FDA-approved drug for the FDA-approve
Slide 14: Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX
Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX 2011 TPOXX CONTRACT 2018 TPOXX CONTRACT Procurement Duration 2011 - 2018 2018 - 2026 U.S. Biomedical Advanced Research U.S. Biomedical Advanced Research Key Agency Involved and Development Authority (BARDA) and
Slide 15: TPOXX as a PEP Aims to Expand Health Benefits When Exposed to Smallpox
TPOXX as a PEP Aims to Expand Health Benefits When Exposed to Smallpox Totality of data suggests administration is optimal as early as possible or as post-exposure prophylaxis Antiviral Post-Exposure Prophylaxis Antiviral Treatment for Active Infections Vaccines Window Optimally within 3 days but no
Slide 16: Financial Summary
Financial Summary
Slide 17: Strong, Durable Financial Performance Over Time
Strong, Durable Financial Performance Over Time SIGA is Well Product Revenues ($mm) Pre-tax Operating Income ($mm) Positioned Financially $127 $131 $133 $85 $89 $84 Company maintains a $116 $70 strong balance sheet $87 $88 $43 through disciplined cash $24 management and no debt 2020 2021 2022 2023 2
Slide 18: Our Financial Journey: 2020 to 2025
Our Financial Journey: 2020 to 2025 1 U.S. Government Orders ($ in millions) 2020 2021 2022 2023 2024 2025 Product Revenues $546 mm of TPOXX ordered for the SNS Oral TPOXX $30 mm of oral TPOXX ordered by the Department $113 $113 $7 $110 $84 $53 (U.S. Government) of Defense Oral TPOXX $2 $13 $71
Slide 19: Key Takeaways
Key Takeaways Leveraging Building on Driving Organic Expanding Maintaining a Infectious Disease Successful Growth Platform with Robust Foundation TPOXX Franchise Initiatives Inorganic Growth Balance Sheet Leading health security Proven track record of Multiple organic growth Attractive opportunities